Has Tonya Russell, MD received payments from drug or device companies?

Yes. Drug and device makers reported $143 in general payments to Tonya Russell, MD across 1 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tonya Russell, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tonya Russell, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tonya Russell, MD

Pulmonary Disease · Saint Louis, MONPI 1194743906

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Actelion Pharmaceuticals US, Inc.. That places this record below the midpoint for pulmonary disease clinicians in MO, where the typical reported total is $1,482.

$143in general payments, 2019–2025

Across 1 payment — averaging $142.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Actelion Pharmaceuticals US, Inc.$143

$1,022,005in research payments, 2019–2025

Across 234 payments — averaging $4367.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

United Therapeutics Corporation$490K
Boehringer Ingelheim$342K
Roche Products Limited$143K
Novartis$26K
Boehringer Ingelheim International GmbH$13K
Boehringer Ingelheim Pharma GmbH & Co.kg$8K

What the payments were for

Food & beverage$143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Actelion Pharmaceuticals US, Inc.	1	$143

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OPSUMIT$143
UPTRAVI$143

How this compares

$143 in reported general payments places this provider in the 15th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri →

Medicare billing

Part B allowed, 2024

$112,859

Medicare patients

737

Services billed

1,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OfevNintedanib Esylate	148	$2,038,012
Tyvaso DpiTreprostinil	12	$297,602
Pirfenidone	82	$254,605
Aralast NpAlpha-1-Proteinase Inhibitor	13	$142,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	138	$129,233
Breo ElliptaFluticasone/Vilanterol	168	$78,193
Incruse ElliptaUmeclidinium Bromide	96	$49,281
Spiriva HandihalerTiotropium Bromide	51	$40,536
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	62	$36,850
Mycophenolate Mofetil	236	$32,444
Spiriva RespimatTiotropium Bromide	41	$23,282
SymbicortBudesonide/Formoterol Fumarate	53	$20,165
Tiotropium Bromide	27	$14,716
Combivent RespimatIpratropium/Albuterol Sulfate	21	$14,396
Serevent DiskusSalmeterol Xinafoate	20	$11,593

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Saint Louis

Derek ByersSaint Louis$835K
Alexander ChenSaint Louis$679K
Joseph OjileSaint Louis$538K
Edward CharbekSaint Louis$372K
Marin KollefSaint Louis$264K
Praveen ChennaSaint Louis$255K
Murali ChakinalaSaint Louis$172K
Janet LeeSaint Louis$143K
Ali SadoughiSaint Louis$87K
Ramsey HachemSaint Louis$79K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →